enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Rheumatoid arthritis linked to changes in the gut microbiome ...

   www.aol.com/rheumatoid-arthritis-linked-changes...

   Rooney is the lead author of a new study reporting that certain changes to the gut microbiome may be linked to the development of rheumatoid arthritis, potentially opening up a new pathway for ...

3. Adalimumab - Wikipedia

   en.wikipedia.org/wiki/Adalimumab

   Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.

4. Is This New Rheumatoid Arthritis Treatment a Game Changer? - AOL

   www.aol.com/news/2013-10-16-is-this-new...

   Shares of Antares Pharma , a developer of auto injectors and topical gel treatments, rallied on Monday after the company announced that the Food and Drug Administration had approved its Otrexup ...

5. Rheumatoid arthritis - Wikipedia

   en.wikipedia.org/wiki/Rheumatoid_arthritis

   Sulfasalazine also appears to be most effective in the short-term treatment of rheumatoid arthritis. [120] Hydroxychloroquine, in addition to its low toxicity profile, is considered effective for treatment of moderate RA symptoms. [121] Agents may be used in combination, however, people may experience greater side effects.

6. Disease-modifying antirheumatic drug - Wikipedia

   en.wikipedia.org/wiki/Disease-modifying_anti...

   Although the use of the term DMARDs was first propagated in rheumatoid arthritis (hence their name), the term has come to pertain to many other diseases, such as Crohn's disease, lupus erythematosus, Sjögren syndrome, immune thrombocytopenic purpura, myasthenia gravis, sarcoidosis, and various others. [citation needed]

7. Rheumatoid Arthritis Drugs Market Size & Share to Surpass USD ...

   lite.aol.com/tech/story/0022/20241106/9268278.htm

   Compared to traditional disease-modifying antirheumatic drugs (DMARDs), these drugs target specific immune system components involved in rheumatoid arthritis, providing better results and fewer side effects. The convenience and effectiveness of rheumatoid arthritis treatments could be improved with drug delivery innovations.